Page last updated: 2024-10-24

butacaine and Parkinson Disease

butacaine has been researched along with Parkinson Disease in 1 studies

butacaine: was MH 1965-92; BUTAPROBENZ & BUTOCAIN were see BUTACAINE 1978-92; use 4-AMINOBENZOIC ACID to search BUTACAINE 1966-92

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kristal, BS1
Conway, AD1
Brown, AM1
Jain, JC1
Ulluci, PA1
Li, SW1
Burke, WJ1

Other Studies

1 other study available for butacaine and Parkinson Disease

ArticleYear
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
    Free radical biology & medicine, 2001, Apr-15, Volume: 30, Issue:8

    Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Aminobenzoic Acid; Aminobenzoates; Animals; Aristolochic Acids; Ce

2001